Humacyte (NASDAQ:HUMA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) from a sell rating to a hold rating in a research note published on Thursday.

A number of other equities research analysts also recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Tuesday, May 13th. Benchmark lowered their price objective on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Finally, HC Wainwright started coverage on Humacyte in a research note on Wednesday, May 14th. They issued a “buy” rating and a $4.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.71.

Humacyte Stock Performance

Shares of HUMA stock opened at $2.40 on Thursday. Humacyte has a 52-week low of $1.15 and a 52-week high of $9.97. The company has a market capitalization of $372.29 million, a PE ratio of -1.79 and a beta of 1.64. The business’s fifty day moving average is $1.78 and its 200 day moving average is $3.41.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.46 million. On average, sell-side analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Activity at Humacyte

In other news, Director Kathleen Sebelius bought 50,000 shares of Humacyte stock in a transaction that occurred on Tuesday, April 8th. The shares were acquired at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now directly owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Dale A. Sander acquired 20,000 shares of Humacyte stock in a transaction dated Thursday, April 10th. The shares were bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares of the company’s stock, valued at approximately $62,118. The trade was a 97.09% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock valued at $118,224 over the last 90 days. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Vontobel Holding Ltd. bought a new position in shares of Humacyte during the fourth quarter valued at about $50,000. Petros Family Wealth LLC bought a new position in shares of Humacyte during the fourth quarter valued at about $50,000. Syon Capital LLC bought a new position in shares of Humacyte during the fourth quarter valued at about $54,000. Ameriprise Financial Inc. bought a new position in shares of Humacyte during the fourth quarter valued at about $58,000. Finally, Hsbc Holdings PLC bought a new position in shares of Humacyte during the fourth quarter valued at about $62,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.